Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gedatolisib + Paclitaxel + Carboplatin in Advanced NSCLC
NCT02920450Phase 2Terminated
- Sponsor
- University of Florida
- Start
- Sep 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gedatolisib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by University of Florida. Primary endpoints: Dose Tolerability at 1 year and Objective Response Rate at 1 year. Started Sep 2017; status: terminated.
02
Drugs
gedatolisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02920450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02920450.